Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

Few of the many nonpharmacologic efforts to mitigate the spread of COVID-19 in nursing homes during the pandemic were evidence-based, and vaccinations and antiviral drugs were underused, concludes a ...

Hopkins researchers help secure full FDA approval to treat immunocompromised COVID-19 patients—paving the way to explore ...

New research showed some long COVID patients get symptom relief by taking an extended course of Paxlovid. Data are ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

A data point is marked as “insufficient data” if wastewater samples test negative for a virus (because levels are too low to ...

Since the pandemic, drug trials that purposely make people vomit, shiver and ache have become a research area of growing ...

Invivyd (IVVD) announced positive data from its ongoing Phase 1/2 clinical trial of VYD2311, Invivyd’s novel monoclonal antibody candidate ...

The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal ...

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 ...